AR066649A1 - Reovirus mutantes y metodos de elaboracion y uso de los mismos - Google Patents
Reovirus mutantes y metodos de elaboracion y uso de los mismosInfo
- Publication number
- AR066649A1 AR066649A1 ARP080102139A ARP080102139A AR066649A1 AR 066649 A1 AR066649 A1 AR 066649A1 AR P080102139 A ARP080102139 A AR P080102139A AR P080102139 A ARP080102139 A AR P080102139A AR 066649 A1 AR066649 A1 AR 066649A1
- Authority
- AR
- Argentina
- Prior art keywords
- reovirus
- methods
- elaboration
- mutants
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un reovirus mutante, CARACTERIZADO PORQUE dicho reovirus mutante comprende una primera mutacion, en donde dicha primera mutacion reduce la expresion de un polipéptido sigma3, elimina esencialmente la expresion de un polipéptido sigma3 o da como resultado la ausencia de un polipéptido sigma3 funcional. Reivindicacion 9: Una partícula subviral infecciosa (ISVP) de reovirus, CARACTERIZADA PORQUE fue manipulada genéticamente. También se proveen composiciones que incluyen reovirus mutantes y métodos de uso de dichos reovirus mutantes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93925507P | 2007-05-21 | 2007-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066649A1 true AR066649A1 (es) | 2009-09-02 |
Family
ID=40031362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102139A AR066649A1 (es) | 2007-05-21 | 2008-05-20 | Reovirus mutantes y metodos de elaboracion y uso de los mismos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20080292594A1 (es) |
EP (1) | EP2150613B1 (es) |
JP (1) | JP2010527593A (es) |
CN (2) | CN101679953A (es) |
AR (1) | AR066649A1 (es) |
AU (1) | AU2008253505B2 (es) |
CA (1) | CA2680661C (es) |
DK (1) | DK2150613T3 (es) |
ES (1) | ES2611455T3 (es) |
HK (1) | HK1136006A1 (es) |
IL (1) | IL200690A (es) |
MX (1) | MX2009012420A (es) |
TW (1) | TW200909581A (es) |
WO (1) | WO2008141448A1 (es) |
ZA (1) | ZA200907017B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0720624D0 (en) * | 2007-10-20 | 2007-11-28 | Academisch Ziekenhuis Leiden | Viral Modification |
AU2008316276A1 (en) * | 2007-10-22 | 2009-04-30 | Oncolytics Biotech Inc. | Treatment regime for proliferative disorders |
EP2296679A4 (en) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY |
US20110086005A1 (en) * | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
TW201233803A (en) | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
JP6034798B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 液体ウイルス製剤 |
ES2796950T3 (es) | 2013-11-15 | 2020-11-30 | Oncolytics Biotech Inc | Virus oncolíticos y regímenes reforzados para tratamiento de cáncer |
AU2017221592A1 (en) | 2016-02-16 | 2018-10-04 | Osaka University | Pharmaceutical composition for use in treating fibrosis |
KR20210098202A (ko) * | 2020-01-31 | 2021-08-10 | 바이로큐어 주식회사 | 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
PT1098961E (pt) * | 1998-06-12 | 2008-04-23 | Mount Sinai School Of Med Of T | Vírus atenuados produzidos por engenharia genética indutores de interferão |
TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
DE60142485D1 (de) * | 2000-11-09 | 2010-08-12 | Oncolytics Biotech Inc | Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen |
CA2437962C (en) * | 2001-03-16 | 2005-11-15 | Oncolytics Biotech Inc. | Method of extracting virus from cell culture |
US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
US10260049B2 (en) * | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
-
2008
- 2008-05-20 TW TW097118468A patent/TW200909581A/zh unknown
- 2008-05-20 AR ARP080102139A patent/AR066649A1/es unknown
- 2008-05-21 MX MX2009012420A patent/MX2009012420A/es active IP Right Grant
- 2008-05-21 CN CN200880016669A patent/CN101679953A/zh active Pending
- 2008-05-21 CN CN201410339446.7A patent/CN104195115A/zh active Pending
- 2008-05-21 AU AU2008253505A patent/AU2008253505B2/en active Active
- 2008-05-21 DK DK08748334.3T patent/DK2150613T3/en active
- 2008-05-21 EP EP08748334.3A patent/EP2150613B1/en active Active
- 2008-05-21 WO PCT/CA2008/000964 patent/WO2008141448A1/en active Application Filing
- 2008-05-21 US US12/124,522 patent/US20080292594A1/en not_active Abandoned
- 2008-05-21 JP JP2010508676A patent/JP2010527593A/ja active Pending
- 2008-05-21 CA CA2680661A patent/CA2680661C/en active Active
- 2008-05-21 ES ES08748334.3T patent/ES2611455T3/es active Active
-
2009
- 2009-09-02 IL IL200690A patent/IL200690A/en active IP Right Grant
- 2009-10-08 ZA ZA2009/07017A patent/ZA200907017B/en unknown
-
2010
- 2010-02-24 HK HK10101956.8A patent/HK1136006A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL200690A0 (en) | 2011-08-01 |
DK2150613T3 (en) | 2017-01-30 |
EP2150613B1 (en) | 2016-10-19 |
ZA200907017B (en) | 2010-12-29 |
CN101679953A (zh) | 2010-03-24 |
TW200909581A (en) | 2009-03-01 |
CA2680661A1 (en) | 2008-11-27 |
IL200690A (en) | 2014-02-27 |
MX2009012420A (es) | 2009-12-09 |
ES2611455T3 (es) | 2017-05-09 |
WO2008141448A1 (en) | 2008-11-27 |
US20080292594A1 (en) | 2008-11-27 |
HK1136006A1 (zh) | 2010-06-18 |
JP2010527593A (ja) | 2010-08-19 |
EP2150613A4 (en) | 2011-01-19 |
EP2150613A1 (en) | 2010-02-10 |
AU2008253505B2 (en) | 2014-09-04 |
AU2008253505A1 (en) | 2008-11-27 |
CN104195115A (zh) | 2014-12-10 |
CA2680661C (en) | 2018-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066649A1 (es) | Reovirus mutantes y metodos de elaboracion y uso de los mismos | |
WO2008036374A3 (en) | Allogeneic stem cell transplants in non-conditioned recipients | |
WO2018226732A8 (en) | MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF | |
ATE553792T1 (de) | Medizinische vorrichtungen mit verbundstoffen | |
MXPA05013973A (es) | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. | |
AR064725A1 (es) | Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso | |
DE60143517D1 (de) | Wiederherstellung der gelenken mit mesenchymalen stammzellen | |
WO2008118392A3 (en) | Synthetic cell platforms and methods of use thereof | |
HN2005029978A (es) | Formulaciones | |
AU2008326599A8 (en) | Modulation of the immune response | |
WO2002009650A3 (en) | Methods and compositions for the repair and/or regeneration of damaged myocardium | |
NO20085396L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
SG127836A1 (en) | Light diffusing films, methods of making the same,and articles using the same | |
ECSP088831A (es) | Anticuerpos anti-tat226 e inmunoconjugados | |
AR054937A1 (es) | Goma de mascar biodegradable | |
SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
BR112021019349A2 (pt) | Células-tronco preparadas altamente funcionais | |
ECSP088203A (es) | Dispersiones amorfas sólidas | |
TW200703884A (en) | Miller-compensated amplifier | |
WO2002013760A3 (en) | Methods and compositions for the repair and/or regeneration of damaged myocardium | |
WO2007078879A3 (en) | Lipopeptide compositions and methods of use thereof | |
SV2006002220A (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd | |
MX2008011844A (es) | Formulaciones de sitaxsentano de sodio. | |
WO2005086938A3 (en) | Artificial mutation controls for diagnostic testing | |
WO2008120201A3 (en) | An isolated population of cells and methods of generating and using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |